3D quantification of nash-related liver fibrosis using open-top light-sheet microscopy
Ended Project Grant Awarded Last action
- Award ID
- R43DK130751
- Recipient
-
Alpenglow Biosciences, Inc. UEI DVN2AF9A1YV3
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $808,016
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Funding
-
- $538,665.33 Federal
- $269,351.00 Non-federal
- Place of performance
- Seattle, WA 98195, USA
Award details come from USAspending.gov.
Description
- Abstract
- Non-alcoholic fatty liver disease (NAFLD) prevalence is estimated at >25% in the U.S., making IT the most common cause of chronic liver disease. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, affects 1-3% of the U.S. Population and is expected to double by 2030. Currently, there is no effective pharmacotherapy for NAFLD, but there are numerous promising drug candidates being evaluated in clinical trials. However, the primary endpoint for these trials, histologic fibrosis, has shortcomings including sampling error and use of a subjective five category scale to quantify a continuous variable. Our team has pioneered the use of 3D open-top light-sheet (OTLS) microscopy, which enables rapid, high-throughput imaging of large clinical samples. In combination with cutting-edge machine learning techniques, we hypothesize that 3D OTLS microscopy can provide more accurate and consistent assessment of fibrosis in liver biopsies from NASH patients. We will test this hypothesis by developing a multiplex staining protocol and machine learning analysis pipeline, which will be piloted on 20 archived ffpe liver biopsies. Results from our assay will be correlated with currently used primary and secondary outcome measures to motivate further studies with sing archived samples from clinical trials with responsivity and outcomes data.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$37 | $0 | |
| Amendment | $269,351 | $0 | |
| Original award | $269,351 | $269,351 |
Quick answers
Who received award R43DK130751?
R43DK130751 was awarded to Alpenglow Biosciences, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 20, 2021.
How much is award R43DK130751 worth?
$808,016 has been obligated on R43DK130751: $538,665 in federal funding and $269,351 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award